Advanced search
Publication Cover
The American Journal of Drug and Alcohol Abuse
Encompassing All Addictive Disorders
Volume 49, 2023 - Issue 3: Drug or alcohol-induced neuroinflammation: insights from pre-clinical models and clinical research
Submit an article Journal homepage
247
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Baseline C-reactive protein levels are predictive of treatment response to a neuroimmune modulator in individuals with an alcohol use disorder: a preliminary study

Erica N. Grodina Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0001-5528-4918View further author information
ORCID Icon,
Lindsay R. Mereditha Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0001-7584-9488View further author information
ORCID Icon,
Elizabeth M. Burnettea Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USA;b Neuroscience Interdepartmental Program, University of California at Los Angeles, Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0003-4005-5885View further author information
ORCID Icon,
Karen Miottoc Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0003-0252-6383View further author information
ORCID Icon,
Michael R. Irwina Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USA;c Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA;d Jane & Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA;e Cousins Center for Psychoneuroimmunology, University of California at Los Angeles, Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0002-1502-8431View further author information
ORCID Icon &
Lara A. Raya Department of Psychology, University of California at Los Angeles, Los Angeles, CA, USA;c Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA;f Brain Research Institute, University of California, Los Angeles, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5734-9444View further author information
ORCID Icon
Pages 333-344 | Received 29 Mar 2022, Accepted 12 Sep 2022, Published online: 25 Oct 2022

References

  • Mayfield J, Harris RA. The Neuroimmune basis of excessive alcohol consumption. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol. 2017;42:376. doi:10.1038/npp.2016.177.
  • Litten RZ, Ryan ML, Falk DE, Reilly M, Fertig JB, Koob GF. Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin Exp Res. 2015;39:579–84.
  • Cui C, Grandison L, Noronha A. Neuroimmune mechanisms of brain function and alcohol related disorders. Brain Behav Immun. 2011;25:S1–3.
  • Cui C, Shurtleff D, Harris RA. Neuroimmune mechanisms of alcohol and drug addiction. Int Rev Neurobiol. 2014;118:1–12.
  • Meredith LR, Burnette EM, Grodin EN, Irwin MR, Ray LA. Immune treatments for alcohol use disorder: a translational framework. Brain Behav Immun. 2021;97:349–64.
  • Mayfield J, Ferguson L, Harris RA. Neuroimmune signaling: a key component of alcohol abuse. Curr Opin Neurobiol. 2013;23:513–20.
  • Crews FT, Sarkar DK, Qin L, Zou J, Boyadjieva N, Vetreno RP. Neuroimmune function and the consequences of alcohol exposure. Alcohol Res. 2015;37:331–51.
  • Alfonso-Loeches S, Pascual-Lucas M, Blanco AM, Sanchez-Vera I, Guerri C. Pivotal role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage. J Neurosci: Off J Soc Neurosci. 2010;30:8285–95. doi:10.1523/JNEUROSCI.0976-10.2010.
  • Blednov YA, Da Costa AJ, Harris RA, Messing RO. Apremilast alters behavioral responses to ethanol in mice: II. Increased sedation, Intoxication, and reduced acute functional tolerance. Alcohol Clin Exp Res. 2018;42:939–51.
  • Briones TL, Woods J. Chronic binge-like alcohol consumption in adolescence causes depression-like symptoms possibly mediated by the effects of BDNF on neurogenesis. Neurosci. 2013;254:324–34. doi:10.1016/j.neuroscience.2013.09.031.
  • He J, Crews FT. Increased MCP-1 and microglia in various regions of the human alcoholic brain. Exp Neurol. 2008;210:349–58.
  • Achur RN, Freeman WM, Vrana KE. Circulating cytokines as biomarkers of alcohol abuse and alcoholism. J Neuroimmune Pharmacol. 2010;5:83–91.
  • Liu J, Lewohl JM, Harris RA, Iyer VR, Dodd PR, Randall PK, Mayfield RD. Patterns of gene expression in the frontal cortex discriminate alcoholic from nonalcoholic individuals. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol. 2006;31:1574–82. doi:10.1038/sj.npp.1300947.
  • Robinson G, Most D, Ferguson LB, Mayfield J, Harris RA, Blednov YA. Neuroimmune pathways in alcohol consumption: evidence from behavioral and genetic studies in rodents and humans. Int Rev Neurobiol. 2014;118:13–39.
  • Niemelä O, Nivukoski U, Bloigu A, Bloigu R, Aalto M, Laatikainen T. Laboratory test based assessment of WHO alcohol risk drinking levels. Scand J Clin Lab Invest. 2019;79:58–64.
  • Rhodes B, Fürnrohr BG, Vyse TJ. C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol. 2011;7:282–89.
  • Devaraj S, Yun JM, Duncan-Staley C, Jialal I. C-reactive protein induces M-CSF release and macrophage proliferation. J Leukoc Biol. 2009;85:262–67.
  • Heberlein A, Käser M, Lichtinghagen R, Rhein M, Lenz B, Kornhuber J, Bleich S, Hillemacher T. TNF-α and IL-6 serum levels: neurobiological markers of alcohol consumption in alcohol-dependent patients? Alcohol. 2014;48:671–76. doi:10.1016/j.alcohol.2014.08.003.
  • Aziz N, Fahey JL, Detels R, Butch AW. Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood. Clin Diagn Lab Immunol. 2003;10:652–57.
  • Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi-Clarke SL, Robinson AP. CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med. 2009;7:102.
  • Felger JC, Haroon E, Patel TA, Goldsmith DR, Wommack EC, Woolwine BJ, Le NA, Feinberg R, Tansey MG, Miller AH. What does plasma CRP tell us about peripheral and central inflammation in depression? Mol Psychiatry. 2020;25:1301–11.
  • Felger JC, Li Z, Haroon E, Woolwine BJ, Jung MY, Hu X, Miller AH. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol Psychiatry. 2016;21:1358–65.
  • Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med. 2019;49:1958–70.
  • Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–86.
  • Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136–41. doi:10.1093/clinchem/45.12.2136.
  • Luan YY, Yao YM. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Front Immunol. 2018;9:1302.
  • Doumatey AP, Zhou J, Adeyemo A, Rotimi C. High sensitivity C-reactive protein (HS-CRP) remains highly stable in long-term archived human serum. Clin Biochem. 2014;47:315–18. doi:10.1016/j.clinbiochem.2013.12.014.
  • Ishikawa S, Kayaba K, Gotoh T, Nakamura Y, Kario K, Ito Y, Kajii E. Comparison of C-reactive protein levels between serum and plasma samples on long-term frozen storage after a 13.8 year interval: the JMS cohort study. J Epidemiol. 2007;17:120–24. doi:10.2188/jea.17.120.
  • Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circ. 2003;107:363–69. doi:10.1161/01.CIR.0000053730.47739.3C.
  • Ray LA, Roche DJO, Heinzerling K, Shoptaw S. Opportunities for the development of neuroimmune therapies in addiction. Int Rev Neurobiol. 2014;118:381–401.
  • Litten RZ, Falk DE, Ryan ML, Fertig JB. Discovery, development, and adoption of medications to treat alcohol use disorder: goals for the phases of medications development. Alcohol Clin Exp Res. 2016;40:1368–79.
  • Bell RL, Lopez MF, Cui C, Egli M, Johnson KW, Franklin KM, Becker HC. Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. Addict Biol. 2015;20:38–42. doi:10.1111/adb.12106.
  • Ray LA, Bujarski S, Shoptaw S, Roche DJO, Heinzerling K, Miotto K. Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: a randomized, placebo-controlled, human laboratory trial. Neuropsychopharmacology. 2017;42:1776–88. doi:10.1038/npp.2017.10.
  • Grodin EN, Bujarski S, Towns B, Burnette E, Nieto S, Lim A, Lin J, Miotto K, Gillis A, Irwin MR, et al. Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial. Transl Psychiatry. 2021;11:355. doi:10.1038/s41398-021-01478-5.
  • Gibson LCD, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A, Mackenzie FL, Nagasawa M, Stevens PA, Mackenzie SJ. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol. 2006;538:39–42.
  • Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodsdon ME, Bucala R, Cappello M, Gross M, Gaeta F, et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci U S A. 2010;107:11313–18. doi:10.1073/pnas.1002716107.
  • Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, Bucala R. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A. 2002;99:345–50. doi:10.1073/pnas.012511599.
  • Hertz AL, Bender AT, Smith KC, Gilchrist M, Amieux PS, Aderem A, Beavo JA. Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages. Proc Natl Acad Sci U S A. 2009;106:21978–83. doi:10.1073/pnas.0911684106.
  • Gobejishvili L, Barve S, Joshi-Barve S, McClain C. Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2008;295:G718–724.
  • Logrip ML. Phosphodiesterase regulation of alcohol drinking in rodents. Alcohol. 2015;49:795–802. doi:10.1016/j.alcohol.2015.03.007.
  • Logrip ML, Vendruscolo LF, Schlosburg JE, Koob GF, Zorrilla EP. Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol. 2014;39:1722–31. doi:10.1038/npp.2014.20.
  • Burnette EM, Ray LA, Irwin MR, Grodin EN. Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder. Alcohol Clin Exp Res. 2021;45:2017–28.
  • Grodin EN, Nieto SJ, Meredith LR, Burnette E, O’Neill J, Alger J, London ED, Miotto K, Evans CJ, Irwin MR, et al. Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: a randomized clinical trial. Addict Biol. 2022;27:e13182. doi:10.1111/adb.13182.
  • Leggio L, Kenna GA, Fenton M, Bonenfant E, Swift RM. Typologies of alcohol dependence. From jellinek to genetics and beyond. Neuropsychol Rev. 2009;19:115–29.
  • Mann K, Vollstädt-Klein S, Reinhard I, Leménager T, Fauth-Bühler M, Hermann D, Hoffmann S, Zimmermann US, Kiefer F, Heinz A, et al. Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging. Alcohol Clin Exp Res. 2014;38:2754–62.
  • Witkiewitz K, Roos CR, Mann K, Kranzler HR. Advancing precision medicine for alcohol use disorder: replication and extension of reward drinking as a predictor of naltrexone response. Alcohol Clin Exp Res. 2019;43:2395–405.
  • Agabio R, Pisanu C, Gessa GL, Franconi F. Sex differences in alcohol use disorder. Curr Med Chem. 2017;24:2661–70.
  • Heilig M, Leggio L. What the alcohol doctor ordered from the neuroscientist: theragnostic biomarkers for personalized treatments. Prog Brain Res. 2016;224:401–18.
  • Chamberlain SR, Cavanagh J, de Boer P, Mondelli V, Jones DNC, Drevets WC, Cowen PJ, Harrison NA, Pointon L, Pariante CM, et al. Treatment-resistant depression and peripheral C-reactive protein. Br J Psychiatry. 2019;214:11–19.
  • Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41. doi:10.1001/2013.jamapsychiatry.4.
  • Halaris A, Sohl E, Whitham EA. Treatment-resistant depression revisited: a glimmer of hope. J Pers Med. 2021;11:155.
  • Liu JJ, Wei YB, Strawbridge R, Bao Y, Chang S, Shi L, Que J, Gadad BS, Trivedi MH, Kelsoe JR, et al. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. Mol Psychiatry. 2020;25:339–50.
  • Burrows K, Stewart JL, Kuplicki R, Figueroa-Hall L, Spechler PA, Zheng H, Guinjoan SM, Savitz JB, Kent Teague T, Paulus MP. Elevated peripheral inflammation is associated with attenuated striatal reward anticipation in major depressive disorder. Brain Behav Immun. 2021;93:214–25.
  • Liu Q, Ely B, Simkovic S, Tao A, Wolchok R, Alonso CM, Gabbay V. Correlates of C-reactive protein with neural reward circuitry in adolescents with psychiatric symptoms. Brain, Behav Immun - Health. 2020;9:100153.
  • First M, Williams J, Karg R, Spitzer R. Structured clinical interview for DSM-5—research version (SCID-5 for DSM-5, research version; SCID-5-RV). Arlington (VA): American Psychiatric Association; 2015. p. 1–94.
  • Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA‐Ar). Br J Addict. 1989;84:1353–57. doi:10.1111/j.1360-0443.1989.tb00737.x.
  • Sobell LC, Sobell MB. Timeline follow-back. In: Measuring alcohol consumption. Springer; 1992. p. 41–72.
  • Saunders JB, Aasland OG, Babor TF, De la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption‐II. Addict. 1993;88:791–804. doi:10.1111/j.1360-0443.1993.tb02093.x.
  • Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H. Stability of fMRI striatal response to alcohol cues: a hierarchical linear modeling approach. Neuroimage. 2011;56:61–68. doi:10.1016/j.neuroimage.2011.02.004.
  • Woolrich MW, Ripley BD, Brady M, Smith SM. Temporal autocorrelation in univariate linear modeling of FMRI data. Neuroimage. 2001;14:1370–86. doi:10.1006/nimg.2001.0931.
  • Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM. Multilevel linear modelling for FMRI group analysis using Bayesian inference. Neuroimage. 2004;21:1732–47.
  • Worsley KJ. Statistical analysis of activation images. Funct MRI. 2001;14:251–70.
  • Avila DV, Myers SA, Zhang J, Kharebava G, McClain CJ, Kim HY, Whittemore SR, Gobejishvili L, Barve S. Phosphodiesterase 4b expression plays a major role in alcohol-induced neuro-inflammation. Neuropharmacol. 2017;125:376–85. doi:10.1016/j.neuropharm.2017.08.011.
  • Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Suzumura A. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004;46:404–11. doi:10.1016/j.neuropharm.2003.09.009.
  • Claus ED, Ewing SWF, Filbey FM, Sabbineni A, Hutchison KE. Identifying neurobiological phenotypes associated with alcohol use disorder severity. Neuropsychopharmacology. 2011;36:2086–96.
  • Al-Khalil K, Vakamudi K, Witkiewitz K, Claus ED. Neural correlates of alcohol use disorder severity among nontreatment‐seeking heavy drinkers: an examination of the incentive salience and negative emotionality domains of the alcohol and addiction research domain criteria. Alcohol Clin Exp Res. 2021;45:1200–14. doi:10.1111/acer.14614.
  • Zeng J, Yu S, Cao H, Su Y, Dong Z, Yang X. Neurobiological correlates of cue-reactivity in alcohol-use disorders: a voxel-wise meta-analysis of fMRI studies. Neurosci Biobehav Rev. 2021;128:294–310. doi:10.1016/j.neubiorev.2021.06.031.
  • Bach P, Weil G, Pompili E, Hoffmann S, Hermann D, Vollstädt-Klein S, Mann K, Perez-Ramirez U, Moratal D, Canals S, et al. Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone. Addict Biol. 2020;25:e12717.
  • Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H. Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. Psychopharmacology (Berlin). 2013;227:627–37. doi:10.1007/s00213-013-2996-x.
  • Grodin EN, Ray LA. The use of functional magnetic resonance imaging to test pharmacotherapies for alcohol use disorder: a systematic review. Alcohol Clin Exp Res. 2019;43:2038–56.
  • Lukas SE, Lowen SB, Lindsey KP, Conn N, Tartarini W, Rodolico J, Mallya G, Palmer C, Penetar DM. Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. Neuroimage. 2013;78:176–85. doi:10.1016/j.neuroimage.2013.03.055.
  • Grodin EN, Burnette EM, Green R, Lim AC, Miotto K, Ray LA. Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers. Drug Alcohol Depend. 2021;225:108825.
  • Leclercq S, Cani PD, Neyrinck AM, Stärkel P, Jamar F, Mikolajczak M, Delzenne NM, de Timary P. Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects. Brain Behav Immun. 2012;26:911–18.
  • Meredith LR, Grodin EN, Montoya AK, Miranda JR, Squeglia LM, Towns B, Evans C, Ray LA. The effect of neuroimmune modulation on subjective response to alcohol in the natural environment. Alcohol Clin Exp Res. 2022;46:876–90. doi:10.1111/acer.14821.
  • Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–12.
  • Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuron. 2020;107:234–56.
  • Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2:258–70.
  • Pereira AC, Oliveira J, Silva S, Madeira N, Pereira CMF, Cruz MT. Inflammation in bipolar disorder (BD): identification of new therapeutic targets. Pharmacol Res. 2021;163:105325.
  • Adams C, Conigrave JH, Lewohl J, Haber P, Morley KC. Alcohol use disorder and circulating cytokines: a systematic review and meta-analysis. Brain Behav Immun. 2020;89:501–12.
  • Ray LA, Bujarski S, Yardley MM, Roche DJ, Hartwell EE. Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter? Am J Drug Alcohol Abuse. 2017;43:703–10.
  • Rohn MC, Lee MR, Kleuter SB, Schwandt ML, Falk DE, Leggio L. Differences between treatment‐seeking and nontreatment‐seeking alcohol‐dependent research participants: an exploratory analysis. Alcohol Clin Exp Res. 2017;41:414–20.
  • Litten RZ, Falk DE, Ryan ML, Fertig J, Leggio L. Five priority areas for improving medications development for alcohol use disorder and promoting their routine use in clinical practice. Alcohol Clin Exp Res. 2020;44:23–35.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.